Search Results

A yellow color poster having 'obesity' written over it.
Fitness and Wellness

Global Obesity Tops 1 Billion: WHO Warns GLP-1 Drugs Are Not a Standalone Solution

MBT Desk
3 min read
WHO’s first guideline on GLP-1 therapies warns that weight-loss drugs alone won’t solve obesity, urging comprehensive care, healthy habits, and safer access policies
A blue and white syringe featuring a white tip, designed for medical use.
USA

Making GLP-1 Weight Loss Drugs Cheaper Isn’t Enough to Address America’s Obesity Problem Here’s Why

MBT Desk
5 min read
Lower drug prices alone won’t solve obesity without broader policy changes and prevention efforts.
An image of the building of the headquarters of WHO.
Fitness and Wellness

GLP-1 Drugs and Immunotherapies Now on WHO’s Essential Medicines List

MBT Desk
2 min read
WHO expands access by including immunotherapies and GLP-1 agonists in its EML for broader global health equity.
A recent study in GLP-1 drugs potentially improved surgical complications and recovery in diabetes patients (Representational Image: Pexels)
Medicine

New Study Reveals Benefits of GLP-1 Drugs, Reducing Post-Surgery Complications in Diabetes Patients

Dr. Disha Merlyn Mathias
3 min read
A possibility for improving surgical complications in diabetic patients
Bariatric surgery found to be more effective than GLP-1 drugs in reducing kidney disease progression, according to a recent study. (Representational image: Wikimedia Commons)
Medicine

Bariatric Surgery Shows Greater Effectiveness than GLP-1 Drugs in Slowing Kidney Disease Progression

Ankur Deka
3 min read
Study finds bariatric surgery significantly reduces risk of chronic kidney disease progression compared to GLP-1 drugs in patients with obesity and diabetes
After extensive review, the MHRA concludes no link between popular diabetes drugs like Wegovy and mental health concerns. (Wikimedia Commons)
Medicine

No Suicide Risk Linked to GLP-1 Drugs, Says UK Health Authority After Extensive Review

Ankur Deka
2 min read
MHRA concludes there is no evidence to support a connection between GLP-1 receptor agonists, including Novo Nordisk's Wegovy, and suicide-related risks
Read More
logo
Medbound Times
www.medboundtimes.com